TriangleSL-401 (NCT03113643)
SL-401 trial for Acute Myeloid Leukemia (NCT03113643). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Older adults with acute myeloid leukemia often get two drugs, azacitidine and venetoclax. Remissions come, but many fade, especially with a TP53 mutation.
The idea: add a third drug that carries a bacterial toxin straight into leukemia cells.
Tagraxofusp is interleukin-3, a growth signal these cells crave, fused to diphtheria toxin. Cells carrying the CD123 receptor pull it in and die. It is already approved for a rare leukemia. In the lab, azacitidine re-sensitized resistant cells and left them leaning on BCL-2, venetoclax's target.
In fifty-six adults, the triplet was tolerable; in untreated high-risk AML, sixty-nine percent responded, including half of those with TP53 mutations.
Andrew Lane leads it at Dana-Farber, with City of Hope and MD Anderson. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.